MedPath

Intercostal Cryoanalgesia for Chronic Pain After VATS Lung Resection

Not Applicable
Completed
Conditions
Lung Cancer
Cryotherapy Effect
Surgery
Chronic Pain
Registration Number
NCT05884099
Lead Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Brief Summary

Intercostal cryoanalgesia is a technique that allows extensive and prolonged analgesia of the hemithorax. The aim of this study is to demonstrate the efficacy of intercostal cryoanalgesia as an adjunct to a single-injection paravertebral block for the prevention of chronic thoracic pain after VATS lung resection surgery.

Detailed Description

VATS lung resection is associated with a high incidence of persistent thoracic pain. To our knowledge, there is no study on the effect of cryoanalgesia on the incidence and severity of chronic thoracic pain 3 months after VATS lung resection.

Intercostal cryoanalgesia is a technique that allows extensive and prolonged analgesia of the hemithorax. In a recent study by Ilfeld \& al, intercostal cryoanalgesia (combined with a single-injection paravertebral block) was able to drastically lower the incidence of chronic pain after total mastectomy compared to the use of the paravertebral block alone (3% vs 17%).

The aim of this study is to demonstrate the efficacy of intercostal cryoanalgesia for the prevention of chronic thoracic pain after VATS lung resection surgery.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Patients scheduled for elective anatomical pulmonary resection (anatomical segmentectomy, lobectomy or bilobectomy) by VATS for lung cancer
  • American Society of Anesthesiologists (ASA) score 1-3
Exclusion Criteria
  • Contraindication to the paravertebral block (coagulopathy, discontinuous paravertebral space, impossible thoracoscopic visualization of the paravertebral space)
  • Contraindication to intercostal cryoanalgesia (cold urticaria, cryoglobulinemia)
  • Epidural analgesia preferred (high risk of thoracotomy, marginal lung function)
  • Surgical criteria (conversion to thoracotomy, non anatomical wedge resection)
  • Preoperative thoracic or shoulder pain on the operated side
  • Known allergy to acetaminophen, celecoxib, sulfa, or both hydromorphone and morphine
  • History of thoracic surgery on the operated site
  • Regular use of opioids or medication with effects against neuropathic pain (tricyclics, gabapentinoids, duloxetine, venlafaxine)
  • Inability to understand pain scales or to communicate clearly despite adequate teaching
  • Contraindication to non-steroidal anti-inflammatory drugs (renal filtration rate < 60 mL/min, active gastric ulcer)
  • Pregnancy
  • Patient refusal to participate

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Incidence of persistent thoracic pain3 months

Persistent postoperative thoracic pain (yes or no)

Secondary Outcome Measures
NameTimeMethod
Incidence of persistent opioid consumption1,3 and 6 months

Persistent postoperative opioid consumption (yes/no)

Incidence of postoperative neuropathic pain48 hours, 1 month and 6 months

DN4 score (10 points) ; positive if 4 points or more

Incidence of new prescription for neuropathic pain medication1, 3 and 6 months

Yes or no

Persistent hypoesthesia over the ipsilateral thorax1 and 6 months

Evaluation of the dermatomal levels of hypoesthesia using a Von Frey monofilament as well as the subjective presence of a sensation of hypoesthesia.

Incidence of persistent thoracic pain1 and 6 months

Persistent postoperative thoracic pain (yes or no)

Severity of persistent thoracic pain1,3 and 6 months

Numerical Rating Scale (NRS) score : scale 0 (no pain) to 10 (worst), at rest and during cough

Trial Locations

Locations (1)

Centre Hospitalier de l'Universite de Montreal

🇨🇦

Montreal, Quebec, Canada

Centre Hospitalier de l'Universite de Montreal
🇨🇦Montreal, Quebec, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.